Optimal Strategies to Estimate the Relative Effectiveness of Influenza Vaccines

Past New Requirement Updated

Agency
Solicitation expected
Not on record
Estimated value
$250,000 to $700,000
Set-aside
No set-aside

Forecast facts

Anticipated award
NAICS code
Not on record
Points of contact

Forecast details come from HHS's procurement forecast. Agencies' dates and values are estimates.

About this forecast

Written by GovTribe AI ·

The Department of Health and Human Services Centers for Disease Control and Prevention (CDC) is forecasting a contract opportunity focused on developing and validating protocols for assessing the relative effectiveness of second-generation influenza vaccines. The project aims to prepare for potential mRNA or third-generation flu vaccine development, contingent upon the success of the FY23 contract, which involves protocol development and recruitment of partner health systems. The estimated award date for this opportunity is July 1, 2025, with a posting date of December 10, 2025.

While specific award values and budget ranges are not provided, the contract appears to involve comprehensive research and protocol validation in the immunization field. The point of contact is Tiffany Tatham-Miller from the National Center for Immunization and Respiratory Diseases (NCIRD), who can be reached at url9@cdc.gov. The research will likely involve multiple health systems and focus on advanced vaccine effectiveness assessment methodologies, though the exact place of performance is not specified in the forecast.

Forecast text

Validation and development of protocol for relative effectiveness of second generation flu vaccines (and preparation for mRNA or 3rd generation flu vaccines contingent upon success of FY23 contract-development of protocol and recruitment of partner health systems

On GovTribe

Work this forecast

  • Track it in your pipeline
  • Find teaming partners
  • Similar forecasts
  • Ask GovTribe AI about this forecast
Try for free Login